No conflict of interest was declared.
Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications†
Article first published online: 4 JAN 2006
Copyright © 2006 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety
Volume 15, Issue 9, pages 641–652, September 2006
How to Cite
Velentgas, P., West, W., Cannuscio, C. C., Watson, D. J. and Walker, A. M. (2006), Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. Pharmacoepidem. Drug Safe., 15: 641–652. doi: 10.1002/pds.1192
- Issue published online: 26 AUG 2006
- Article first published online: 4 JAN 2006
- Manuscript Accepted: 2 AUG 2005
- Manuscript Revised: 22 JUL 2005
- Manuscript Received: 3 MAR 2004
- Merck and Co, Inc.
- COX-2 inhibitors;
- acute coronary syndrome (ACS);
- myocardial infarction (MI)
The purpose of this study was to estimate rates of acute coronary syndrome (ACS), and sudden cardiac death in relation to use of rofecoxib, celecoxib, naproxen, diclofenac, and ibuprofen.
We conducted a retrospective cohort study among 424 584 health plan enrollees ages 40–64 who used non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) by prescription from 1999 to 2001. We used automated medical and pharmacy claims data to compute person-time exposed to study drugs, and to identify hospitalizations for ACS. The primary endpoint was ACS, inclusive of myocardial infarction (MI), unstable angina, and sudden cardiac death as identified through claims data and confirmed through hospital medical records, or through the National Death Index.
Compared with ibuprofen or diclofenac use, the relative risk (RR) of ACS during periods of current rofecoxib use was 1.35 (95%CI 1.09–1.68). For current use of celecoxib, the RR was 1.03 (95%CI 0.83–1.27). Risks in the first 30 days of rofecoxib and celecoxib use were modestly elevated. Rofecoxib use at the 25 mg/day (modal) dose was associated with an elevated risk of ACS (RR 1.54, 95%CI 1.15–2.04), while use at 26–50 mg/day (>modal) was not (RR 0.81, 95%CI 0.41–1.60). There were no increased risks with modal or greater than modal doses of celecoxib or naproxen compared with all doses of ibuprofen or diclofenac combined.
The incidence of ACS was 1.35 times greater during rofecoxib use than use of ibuprofen or diclofenac. No statistically significant elevation in risk was observed with celecoxib use. Naproxen use was not associated with risk of ACS. Copyright © 2005 John Wiley & Sons, Ltd.